Zoetis (ZTS) Cash from Financing Activities (2012 - 2026)
Zoetis (ZTS) reported Cash from Financing Activities of -$840.0 million for Q1 2026, down 24.08% year-over-year from -$1.1 billion in Q1 2025, and down 69.7% quarter-over-quarter from -$495.0 million in Q4 2025.
Zoetis (ZTS) Cash from Financing Activities (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Cash from Financing Activities data on file, last reported at -$840.0 million in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at -$840.0 million, down 24.08% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.0 billion (up 27.73% YoY), and the FY2025 annual result was -$1.9 billion, up 29.7% from the prior year.
- Cash from Financing Activities declined to -$840.0 million in Q1 2026 per ZTS's latest filing, from -$495.0 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $780.0 million in Q4 2022 and troughed at -$1.8 billion in Q1 2023.
- A 5-year average of -$551.9 million and a median of -$545.0 million in 2022 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities surged 348.41% in 2022, then sank 230.64% in 2023.
- A 5-year view of Cash from Financing Activities shows it stood at $780.0 million in 2022, then plunged by 150.9% to -$397.0 million in 2023, then sank by 87.66% to -$745.0 million in 2024, then surged by 33.56% to -$495.0 million in 2025, then slumped by 69.7% to -$840.0 million in 2026.
- Business Quant data shows ZTS's Cash from Financing Activities at -$840.0 million in Q1 2026, -$495.0 million in Q4 2025, and -$134.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 13.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -840.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -1.48 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -86.10 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -65.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 1.47 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -77.88 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | -11.62 Mn |
| 10 | Liquidia | 5.64 Bn | 5.42 Bn | 121.79 Mn | -18.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -840.00 Mn |
| Mar 31, 2026 | -840.00 Mn |
| Dec 31, 2025 | -495.00 Mn |
| Dec 31, 2025 | -495.00 Mn |
| Sep 30, 2025 | -134.00 Mn |
| Sep 30, 2025 | -134.00 Mn |
| Jun 30, 2025 | -564.00 Mn |
| Jun 30, 2025 | -564.00 Mn |
| Mar 31, 2025 | -677.00 Mn |
| Mar 31, 2025 | -677.00 Mn |
| Dec 31, 2024 | -745.00 Mn |
| Dec 31, 2024 | -745.00 Mn |
| Sep 30, 2024 | -628.00 Mn |
| Sep 30, 2024 | -628.00 Mn |
| Jun 30, 2024 | -763.00 Mn |
| Jun 30, 2024 | -763.00 Mn |
| Mar 31, 2024 | -524.00 Mn |
| Mar 31, 2024 | -524.00 Mn |
| Dec 31, 2023 | -397.00 Mn |
| Dec 31, 2023 | -397.00 Mn |